Ensysce Biosciences (NASDAQ: ENSC) is a clinical-stage biotech company strucrured around development of TWO new classes of Opioids - the first in decades which protect against abuse and overdose while providing powerful relief for severe and chronic pain. Using the firm's proprietary technology platforms to develop safer prescription drugs, personnel are leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms - developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysces products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. With a minimal SBIR presence and that some years ago, the platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions.
